ARTICLE
8 February 2017

Omnicare to Pay $28M to Settle Kickback Allegations

DP
Day Pitney LLP

Contributor

Day Pitney LLP logo
Day Pitney LLP is a full-service law firm with more than 300 attorneys in Boston, Connecticut, Florida, New Jersey, New York and Washington, DC. The firm offers clients strong corporate and litigation practices, with experience on behalf of large national and international corporations as well as emerging and middle-market companies. With one of the largest individual clients practices on the East Coast, the firm also has extensive experience assisting individuals and their families, fiduciaries and tax-exempt entities plan for the future.
Day Pitney's Eric Fader was quoted in an October 17 article, "Omnicare to Pay $28M to Settle Kickback Allegations," that appeared in Bloomberg BNA's Pharmaceutical Law & Industry Report, Health Care Fraud Report and other publications.
United States Food, Drugs, Healthcare, Life Sciences

Day Pitney's Eric Fader was quoted in an October 17 article, "Omnicare to Pay $28M to Settle Kickback Allegations," that appeared in Bloomberg BNA's Pharmaceutical Law & Industry Report, Health Care Fraud Report and other publications. The article discusses the $28 million settlement that Omnicare Inc., the largest nursing home pharmacy in the country, reached with the U.S. Department of Justice (DOJ) to resolve claims that it accepted kickbacks from Abbott Laboratories, a pharmaceutical manufacturer, to induce Omnicare to order one of Abbott's drugs.

Eric said he's not sure how the companies thought they could get away with Abbott paying, and Omnicare accepting, volume-based rebates, kickbacks disguised as educational program contributions, paid Florida vacations and sporting event tickets, all of which violate federal law and long-standing published regulatory guidance. "This case is going to be taught in law school health law courses for a very long time because it has a little of everything, from a regulatory standpoint," Eric predicted.

Still, the two Abbott cases (this one against Omnicare and a previously settled case against PharMerica) may be viewed as outliers that may not have much demonstrable impact on the industry, because all pharmaceutical companies should have already known that these marketing practices simply aren't permitted.

The DOJ's original press release announcing the False Claims Act complaint against Omnicare may be found here.


For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.


Click here for more Healthcare Blogs from Day Pitney

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More